Cargando…

A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11

The present study identified the clinical features of the largest multiple endocrine neoplasia type 2 (MEN2) A pedigree from China, with a novel double missense rearranged during transfection (RET) mutation (C634Y/D707E). To the best of our knowledge, the D707E mutation has not been identified to da...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Fanqian, Chen, Xiaohong, Bai, Yunlong, Feng, Yaru, Wu, Jian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592869/
https://www.ncbi.nlm.nih.gov/pubmed/28943896
http://dx.doi.org/10.3892/ol.2017.6583
_version_ 1783262949127749632
author Lu, Fanqian
Chen, Xiaohong
Bai, Yunlong
Feng, Yaru
Wu, Jian
author_facet Lu, Fanqian
Chen, Xiaohong
Bai, Yunlong
Feng, Yaru
Wu, Jian
author_sort Lu, Fanqian
collection PubMed
description The present study identified the clinical features of the largest multiple endocrine neoplasia type 2 (MEN2) A pedigree from China, with a novel double missense rearranged during transfection (RET) mutation (C634Y/D707E). To the best of our knowledge, the D707E mutation has not been identified to date. In the present study, a total of 101 family members who originated from a large pedigree (134 members in total) underwent RET mutation screening by next-generation sequencing and polymerase chain reaction (PCR) amplification, followed by direct bidirectional DNA sequencing. The clinical features of this pedigree were carefully reviewed retrospectively, and statistical analyses were conducted using SPSS software. A total of 33 (32.67%) carriers were identified to exhibit the C634Y/D707E RET germline mutation. The mean age of the patients with medullary thyroid carcinoma (MTC) identified by RET screening was 38.4±16.5 years (n=11; range, 14–65 years). Only 4 patients with pheochromocytoma with a median age of 37 years were identified. No hyperparathyroidism was diagnosed. Persistent or recurrent disease developed in the patients of the present study who underwent inappropriate initial thyroid surgeries that were performed in previous decades (III10, III23, III24, III27 and IV46, as they had undergone two surgeries prior to the present study). A total of 66.70% (6/9) of patients, following thyroidectomy, continued to develop persistent or recurrent disease during the present screening study. In total, 3 patients succumbed to MTC or distant metastasis in the present study. The increase in carcinoembryonic antigen (CEA) levels correlated with the increase in basal serum calcitonin (Ct) levels according to Pearson correlation analysis in patients with MTC without surgery. Ct and CEA levels were also significantly correlated with tumor volumes. To the best of our knowledge, the present study is the first to identify a novel double RET missense mutation in the largest MEN2A pedigree from China. Additional in-depth study is necessary to elucidate the molecular mechanisms of the D707E mutation and its potential joint effects with the other C634Y mutation in the pedigree of the present study.
format Online
Article
Text
id pubmed-5592869
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-55928692017-09-22 A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11 Lu, Fanqian Chen, Xiaohong Bai, Yunlong Feng, Yaru Wu, Jian Oncol Lett Articles The present study identified the clinical features of the largest multiple endocrine neoplasia type 2 (MEN2) A pedigree from China, with a novel double missense rearranged during transfection (RET) mutation (C634Y/D707E). To the best of our knowledge, the D707E mutation has not been identified to date. In the present study, a total of 101 family members who originated from a large pedigree (134 members in total) underwent RET mutation screening by next-generation sequencing and polymerase chain reaction (PCR) amplification, followed by direct bidirectional DNA sequencing. The clinical features of this pedigree were carefully reviewed retrospectively, and statistical analyses were conducted using SPSS software. A total of 33 (32.67%) carriers were identified to exhibit the C634Y/D707E RET germline mutation. The mean age of the patients with medullary thyroid carcinoma (MTC) identified by RET screening was 38.4±16.5 years (n=11; range, 14–65 years). Only 4 patients with pheochromocytoma with a median age of 37 years were identified. No hyperparathyroidism was diagnosed. Persistent or recurrent disease developed in the patients of the present study who underwent inappropriate initial thyroid surgeries that were performed in previous decades (III10, III23, III24, III27 and IV46, as they had undergone two surgeries prior to the present study). A total of 66.70% (6/9) of patients, following thyroidectomy, continued to develop persistent or recurrent disease during the present screening study. In total, 3 patients succumbed to MTC or distant metastasis in the present study. The increase in carcinoembryonic antigen (CEA) levels correlated with the increase in basal serum calcitonin (Ct) levels according to Pearson correlation analysis in patients with MTC without surgery. Ct and CEA levels were also significantly correlated with tumor volumes. To the best of our knowledge, the present study is the first to identify a novel double RET missense mutation in the largest MEN2A pedigree from China. Additional in-depth study is necessary to elucidate the molecular mechanisms of the D707E mutation and its potential joint effects with the other C634Y mutation in the pedigree of the present study. D.A. Spandidos 2017-09 2017-07-15 /pmc/articles/PMC5592869/ /pubmed/28943896 http://dx.doi.org/10.3892/ol.2017.6583 Text en Copyright: © Lu et al. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Lu, Fanqian
Chen, Xiaohong
Bai, Yunlong
Feng, Yaru
Wu, Jian
A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
title A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
title_full A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
title_fullStr A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
title_full_unstemmed A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
title_short A large Chinese pedigree of multiple endocrine neoplasia type 2A with a novel C634Y/D707E germline mutation in RET exon 11
title_sort large chinese pedigree of multiple endocrine neoplasia type 2a with a novel c634y/d707e germline mutation in ret exon 11
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5592869/
https://www.ncbi.nlm.nih.gov/pubmed/28943896
http://dx.doi.org/10.3892/ol.2017.6583
work_keys_str_mv AT lufanqian alargechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT chenxiaohong alargechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT baiyunlong alargechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT fengyaru alargechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT wujian alargechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT lufanqian largechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT chenxiaohong largechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT baiyunlong largechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT fengyaru largechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11
AT wujian largechinesepedigreeofmultipleendocrineneoplasiatype2awithanovelc634yd707egermlinemutationinretexon11